Recall Enforment Report D-0854-2022

Recall Details

Drug Recall Enforcement Report Class II voluntary initiated by Viatris Inc, originally initiated on 04-28-2022 for the product Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Fizer Inc, NY, NY 10017, NDC 0009-0068-07. The product was recalled due to failed dissolution specifications: low out of specification results for dissolution.. The product was distributed nationwide and the recall is currently terminated.

Field Name Field Value
Event ID 90091 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0854-2022 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Product was distributed nationwide in the USA What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Fizer Inc, NY, NY 10017, NDC 0009-0068-07.
Reason For Recall Failed Dissolution Specifications: low out of specification results for dissolution. What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 110 bottles Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 05-18-2022
Recall Initiation Date 04-28-2022 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Termination Date 07-13-2023 What is the Date Terminated?
The date that FDA terminated the recall.
Initial Firm Notification Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm Viatris Inc
Code Info Lot #: DX7983, exp. date 02/28/2023 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 0009-0057-07; 0009-0059-07; 0009-0066-07; 0009-0068-07
Status Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0009-0057Xanax XRAlprazolamTablet, Extended ReleaseOralPharmacia & Upjohn Company LlcHuman Prescription Drug
0009-0059Xanax XRAlprazolamTablet, Extended ReleaseOralPharmacia & Upjohn Company LlcHuman Prescription Drug
0009-0066Xanax XRAlprazolamTablet, Extended ReleaseOralPharmacia & Upjohn Company LlcHuman Prescription Drug
0009-0068Xanax XRAlprazolamTablet, Extended ReleaseOralPharmacia & Upjohn Company LlcHuman Prescription Drug